Shattuck’s lead partnered compound entered the clinic in April 2019, and its lead wholly-owned compound entered the clinic in August of 2020.
To date, Shattuck’s Agonist Redirected Checkpoint (ARC) platform has yielded more than 300 bi-functional fusion protein drug candidates, two of which are currently in clinical trials for the treatment of life-threatening and debilitating diseases. The two lead ARC molecules are designed to block checkpoint molecules that limit the immune system (PD-1 and CD47) while simultaneously stimulating T-cell receptors to initiate an immune response (OX40 or CD40). Shattuck’s lead partnered asset, SL-279252 (PD1-Fc-OX40L), has advanced to the clinic in less than two years and is currently enrolling patients at five sites across the United States, Canada, and Europe. Shattuck’s internal lead asset, SL-172154 (SIRPα-Fc-CD40L), began enrolling patients in its clinical trials during the second half of 2020.
|Platform||Program||Domain 1||Domain 2||Indications||Discovery||Preclinical||Phase 1||Phase 2||Phase 3||Anticipated Milestones / Status|
Initial Dose Escalation Data 2H'2021
|ARC||SL-172154||SIRPα||CD40L||CSCC and HNSCC(1)|
Initial Dose Escalation Data 1H'2022
|ARC||SL-279252||PD-1||OX40L||Advanced Solid Tumors and Lymphoma|
Dose Escalation Data 2H'2021
|Select Preclinical-Stage Pipeline|
|ARC||SL-115154||CSF1R||CD40L||Advanced Solid Tumors|
|GADLEN||Multiple||γδ TCR||Tumor Antigen||Oncology|
Lead Candidate Selection 2021
(1) Cutaneous Squamous Cell Carcinoma (CSCC) and Head and Neck Squamous Cell Carcinoma (HNSCC)
Takeda holds exclusive options to license SL-279252 and SL-115154